Biodrugs

Papers
(The TQCC of Biodrugs is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond223
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry119
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis83
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor75
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery69
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis55
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome50
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making48
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design48
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?35
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202233
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies32
CAR-T Cells and the Kidney: Insights from the WHO Safety Database31
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic31
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart30
Acknowledgement to Referees30
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials29
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy29
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review28
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data28
Malaria Vaccines: Progress to Date27
Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance25
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network24
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?24
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects24
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer24
Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis22
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience22
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment21
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout21
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options20
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series20
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight19
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?19
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy19
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review19
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study19
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects19
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu18
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis17
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active 17
Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine16
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics15
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (Vig14
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa14
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study14
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review14
Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics14
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials13
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Heal13
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab13
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression12
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis12
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database12
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis12
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases11
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs11
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria11
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine10
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context10
Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilan10
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies10
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing10
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance10
Patients’ Perceptions of Biosimilars: A Systematic Review10
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease10
0.033137083053589